The effect of epostane, a 3-beta hydroxy steroid dehydrogenase inhibitor, on maternal and fetal steroid levels during mid-gestation.
A double-blind, placebo-controlled trial was conducted to assess the maternal and fetal endocrine effects of epostane, an inhibitor of progesterone synthesis, in mid-pregnancy. Although present in the maternal circulation, epostane was not detected in cord blood or amniotic fluid. Maternal and fetal progesterone levels fell by 80% and 95% respectively with maintenance of the fetal arterio-venous difference while oestradiol and aldosterone levels were affected to a lesser extent. The mechanism of 3-beta hydroxy steroid dehydrogenase suppression and the relation between fetal and maternal progesterone levels are discussed.